Company profile: Cleveland Diagnostics
1.1 - Company Overview
Company description
- Provider of efficacious, affordable cancer diagnostic tests, including IsoPSA, a blood test designed to improve the accuracy of prostate cancer detection and reduce unnecessary biopsies by distinguishing cancer-related PSA proteins, and the Solvent Interaction Analysis Platform, which measures structural differences in proteins to identify cancer biomarkers and facilitate development of blood tests for cancer diagnostics.
Products and services
- Solvent Interaction Analysis Platform: Analytical-grade technology that measures protein structural differences to identify cancer biomarkers, enabling creation of blood-based diagnostics tests for cancer
- IsoPSA: Structure-based blood test that improves prostate cancer detection accuracy and reduces unnecessary biopsies by distinguishing cancer-related PSA proteins
- Cancer Diagnostics Test Development: Cost-optimized development of efficacious, affordable blood tests to improve cancer diagnostics, informed by biomarker identification from protein structural differences
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cleveland Diagnostics
Silverback Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies, developing ImmunoTAC treatments targeting previously inaccessible disease pathways, and a needle-free, low-dose intranasal epinephrine nasal spray for use as a rescue medication for people with Type 1 severe allergic reactions including anaphylaxis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Silverback Therapeutics company profile →
ESSA Pharma
HQ: Canada
Website
- Description: Provider of small molecule drugs for cancer treatment, with a focus on advanced prostate cancer, developing therapies that selectively block the N-terminal domain of the androgen receptor, a target required for the growth and survival of most prostate cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ESSA Pharma company profile →
Sofie
HQ: United States
Website
- Description: Provider of molecular imaging, focused on empowering people with new PET technologies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sofie company profile →
Basilea
HQ: Switzerland
Website
- Description: Provider of innovative pharmaceutical products, including Cresemba, an intravenous and oral azole antifungal for invasive aspergillosis and mucormycosis, and Zevtera, an advanced-generation intravenous cephalosporin antibiotic for severe bacterial infections including Staphylococcus aureus bacteremia, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Basilea company profile →
Volition
HQ: United States
Website
- Description: Provider of blood-based cancer diagnostics leveraging Nucleosomics to identify and measure nucleosomes and epigenetic changes for early detection and monitoring. Offerings include Nu.Q® Cancer assays, Nu.Q® NETs for detecting NETosis associated with diseases like sepsis, Nu.Q® Vet Cancer Test for dogs, Nu.Q® Discover for drug developers and scientists, and Capture-PCR™ liquid biopsy isolating tumor-derived ctDNA fragments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Volition company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cleveland Diagnostics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cleveland Diagnostics
2.2 - Growth funds investing in similar companies to Cleveland Diagnostics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cleveland Diagnostics
4.2 - Public trading comparable groups for Cleveland Diagnostics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →